Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
about
First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacyInfectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventionsThe Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the LiteratureBehavioral and biomedical combination strategies for HIV preventionIntegrating prevention interventions for people living with HIV into care and treatment programs: a systematic review of the evidence.A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacyEffects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South AfricaFrequent detection of human adenovirus from the lower gastrointestinal tract in men who have sex with menEpisodic therapy for genital herpes in sub-saharan Africa: a pooled analysis from three randomized controlled trials.Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa.Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations.A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk.Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.Correlates of HIV-1 genital shedding in Tanzanian women.Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings)Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women.Heterosexual anal sexuality and anal sex behaviors: a review.Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South AfricaLong-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.The Interplay between Sexually Transmitted Infections and HIV: An Evolving StoryDetection of hydrogen peroxide-producing Lactobacillus species in the vagina: a comparison of culture and quantitative PCR among HIV-1 seropositive women.Deciphering the epidemic synergy of herpes simplex virus type 2 (HSV-2) on human immunodeficiency virus type 1 (HIV-1) infection among women in sub-Saharan Africa.HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapyCan herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trialAcyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota.Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women.Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania.Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban UgandansEffect of treating co-infections on HIV-1 viral load: a systematic reviewUpdate in HIV medicine for the generalist.Herpes simplex virus type 2 infection increases human immunodeficiency virus type 1 entry into human primary macrophages.Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmissionAddition of Acyclovir does not affect Adherence to HAART in HIV-1/ HSV-2 Co-Infected Women.
P2860
Q21135264-E6E635C4-8411-4C41-9270-CEE59D67469BQ26823594-16BB237E-37CE-4345-9B4B-69CA8C9615FFQ26864344-078061B5-A432-434C-B78D-FF9514863EC5Q27001172-BA03EDB1-C6DE-4DD1-9BC3-B9E82AFC39A1Q27313271-AD444274-85A5-4B4E-B2E3-834DA3E4B646Q27335068-779D496B-AA2A-4141-98BD-267050659D6DQ28728582-AE45E62A-8A1A-4791-A721-4C8590D8E2D2Q28743974-9A4A3EDE-93E4-45D4-A60E-814C34D7BC99Q28751027-90208244-9850-441D-9C9A-DCA92A69D6FEQ31028568-E2E5C933-932D-439F-B932-83FA62C3BFDEQ33336603-8C1AC990-B3D8-4828-A7EC-50FFFFA33B96Q33436735-35DF1D06-7545-46C1-8BBF-A1AD7EC95C7CQ33505667-CA59C57A-864D-4CF0-9B97-76A1602F59E3Q33609662-AAF26158-96F6-4650-86F9-E009FD3D353BQ33697958-EC429247-EE74-417D-A056-7DEB241E474FQ33727305-BC30036C-D7A0-4E99-9C71-D64B73FDF273Q33797142-D24F0657-69FD-477B-8D12-60EDC265BE5AQ33842085-D898AE4A-82BD-40E2-899D-00C8225BFA84Q33881449-C9330CBE-9961-40A0-AD82-2DF65F421E80Q33904091-BCBAABD3-5683-4FCA-8E3F-D221CAF7D698Q33921326-31A44111-1283-40F0-84CA-D4935F511FBBQ34107809-D27A95B3-3565-4D9C-8628-B51589E0F71DQ34168214-5330A050-8F21-46D3-A25F-0B0E470B4391Q34168234-40E08341-A962-4E95-90D2-83C7A973CA89Q34196145-129C99EB-EF0A-4209-B013-8E426A63950EQ34378585-3012D685-B436-4F2B-9D03-F4F8FF48DF2FQ34386832-BD7C4F45-F543-4B6A-AAF7-169340563259Q34389260-98C97D31-B4F4-4DDE-A5C4-44C7D9BB3C09Q34408313-3770D497-D3B6-45E3-81CA-6302F1BDB2A8Q34408370-DABAE4D1-70B1-486C-937A-C342C9B20AA3Q34508433-DE8EC61F-858B-4045-A82D-9C833B2BEC06Q34553877-1106CC37-62AB-4572-AFB6-3918D079CFBEQ34596543-21D090B9-56AF-49BD-BB05-253BF1157D7FQ34630266-5790CF76-1C30-4AB2-A775-07209A329583Q34670442-B9DEE2EC-FAF1-486E-93CE-DC6808419102Q34767216-394C1455-1C60-4FF4-AEC1-A0F4E69F39BAQ34799053-9C650ABF-1B8A-4772-8F3C-BFA644887B10Q34871621-B1359697-28C4-435E-B09C-37492404EE46Q34920252-3F400626-ED93-48AC-BDAC-D56B41308E59Q34978073-24CBE4B7-3514-41EE-9602-E6B483B14871
P2860
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Herpes simplex virus (HSV) sup ...... bo-controlled crossover trial.
@en
Herpes simplex virus (HSV) sup ...... bo-controlled crossover trial.
@nl
type
label
Herpes simplex virus (HSV) sup ...... bo-controlled crossover trial.
@en
Herpes simplex virus (HSV) sup ...... bo-controlled crossover trial.
@nl
prefLabel
Herpes simplex virus (HSV) sup ...... bo-controlled crossover trial.
@en
Herpes simplex virus (HSV) sup ...... bo-controlled crossover trial.
@nl
P2093
P2860
P50
P356
P1476
Herpes simplex virus (HSV) sup ...... bo-controlled crossover trial.
@en
P2093
Amalia S Magaret
Jorge Sanchez
Richard A Zuckerman
Robert W Coombs
Rosario Zuñiga
William L H Whittington
P2860
P304
P356
10.1086/522523
P407
P577
2007-10-31T00:00:00Z